cas 1352447-28-9|| where to buy (S)-2-Amino-2,4-dimethylpentan-1-ol

製品名:(S)-2-Amino-2,4-dimethylpentan-1-ol

IUPAC Name:(2S)-2-amino-2,4-dimethylpentan-1-ol

包装単位	有効在庫	価格（USD）
CM562043-100mg	in stock	ƋƤƤ
CM562043-250mg	in stock	ǲǲſ
CM562043-500mg	1-2 Weeks	ȦƋȦƤ
CM562043-1g	1-2 Weeks	Ȧǆȷſ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1352447-28-9 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1352447-28-9; 分子式:C7H17NO; 融点:-; SMILESコード:CC(C)C[C@](C)(N)CO; 密度:

: カタログ番号:CM562043; 分子量:131.22; 沸点:; MDL番号:; 保管方法:2-8°C, protect from light

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: LX9211; Diabetes Care, a peer-reviewed journal of the American Diabetes Association publishes the data from Lexicon’s RELIEF-DPN 1 phase 2 study of LX9211. Adaptor-Associated Kinase 1 (AAK1) is linked to clathrin-mediated endocytosis, and plays a critical role in neuropathic pain and various neurological disorders.
Lexicon’s LX9211 is a selective small molecule inhibitor of AAK1, that is developed as a novel non-opioid approach to neuropathic pain. LX9211 is designed to become an efficacious treatment for moderate-to-severe pain due to diabetic peripheral neuropathic pain (DPNP), which is difficult to manage with current approved medications.
LX9211 is in late-stage development, and the patient enrollment of Phase 2b study will be completed by 2024. Its top-line data is expected in Q2 2025. Lexicon received Fast Track Designation from the FDA for LX9211 in DPNP in 2020.